Body mass index is a promising predictor of response to oral rehydration saline in children with vasovagal syncope

Chun-Yan Tao1,2, Selena Chen3, Xue-Ying Li4, Chao-Shu Tang5, Jun-Bao Du1,2, Hong-Fang Jin1,2

1Department of Pediatrics, Peking University First Hospital, Beijing 100034, China; 2Research Unit of Clinical Diagnosis and Treatment of Pediatric Syncope and Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing 100730, China; 3Division of Biological Sciences, University of California, San Diego, CA 92093, USA; 4Department of Medical Statistics, Peking University First Hospital, Beijing 100034, China; 5Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing 100191, China.

Abstract

Background: Vasovagal syncope (VVS) greatly impairs quality of life. The therapeutic efficacy of oral rehydration saline (ORS) for unselected VVS patients is not satisfactory due to the diverse mechanisms of the disease. Body mass index (BMI) was demonstrated to reflect blood volume to a certain extent. Therefore, the present study explored the capability of BMI to predict the therapeutic response of children with VVS to ORS treatment.

Methods: Seventy-four children with VVS who visited the Syncope Unit of Pediatrics at Peking University First Hospital from November 2010 to June 2019 receiving ORS treatment were enrolled for this retrospective case-control study. A comparison of demographic, clinical, and hemodynamic characteristics was performed between responders and non-responders. The correlation between baseline BMI and response time was analyzed. To determine the value of baseline BMI in predicting the therapeutic efficacy of ORS in children with VVS, a receiver operating characteristic curve analysis was performed.

Results: Fifty-two children were identified as responders, and the remaining 22 children were identified as non-responders. The baseline BMI of the responders was much lower than that of the non-responders (16.4 [15.5, 17.8] kg/m² vs. 20.7 ± 3.6 kg/m², P < 0.001), and baseline BMI was positively correlated with response time in the head-up tilt test after adjusting for sex (r = 0.256, 95% confidence interval [CI]: 0.067–0.439, P = 0.029). The area under the receiver operating characteristic curve of baseline BMI was 0.818 (95% CI: 0.704–0.932, P < 0.001), and an optimal cut-off value of 18.9 kg/m² yielded a sensitivity of 83% and a specificity of 73% to predict the efficacy of ORS in VVS.

Conclusion: Prior to treatment, baseline BMI is a promising predictor of response to ORS in children with VVS.

Keywords: Vasovagal syncope; Oral rehydration saline; Body mass index; Therapeutic response

Introduction

Vasovagal syncope (VVS) is the most common type of syncope in the pediatric population.1-3 Medical treatment is required when recurrent syncope results in impaired quality of life and unpredictable injuries.4,5 Therefore, determining effective interventions for these patients is important. Oral rehydration saline (ORS) is commonly recommended for children with VVS, but its therapeutic efficacy is unsatisfactory in a significant portion of cases.6,7 A reasonable explanation might be that there are a variety of underlying mechanisms responsible for VVS, such as hypovolemia, abnormal autonomic nervous activity, and vasomotor dysfunction. ORS, administered to increase the body blood volume, may be beneficial for patients with hypovolemia as the main mechanism rather than for those with other underlying mechanisms.8-10 Therefore, ORS treatment for unselected patients lowers its value. To improve the therapeutic efficacy of ORS for VVS in children, it is essential to seek reasonable indicators that predict the hypovolemic condition before treatment.

Body mass index (BMI), a typical and easily obtained anthropometric parameter, can reflect body blood volume to a certain extent, and people with lower BMI are more prone to undergo syncope and respond positively to a head-up tilt test (HUTT).11-16 Therefore, the present study explored the capability of BMI to predict the therapeutic response of children with VVS to ORS.
Methods

Ethical approval

All procedures involving human participants in the study were in line with the 1975 Declaration of Helsinki and its later amendment in 2008, and the present study was authorized by the Ethics Committee of Peking University First Hospital (No. 20181112).

Patients

This was a retrospective case-control study. Seventy-eight patients with VVS who visited the Syncope Unit of Pediatrics at our hospital from November 2010 to June 2019 and underwent ORS treatment were included in the study; they had a median age of 10.0 (8.0, 13.0) years. Detailed histories and physical examinations were obtained routinely, and medical tests, such as blood tests, electrocardiography, Holter electrocardiography, echocardiography, electroencephalography, and intracranial computed tomography (CT) or magnetic resonance imaging (MRI), were performed to exclude cardiogenic or neurologic diseases. VVS was finally diagnosed with the help of the HUTT according to the guidelines provided by the Chinese Pediatric Cardiology Society. The exact diagnostic criteria which have not changed since 2009 were as follows: 1) syncopal episodes; 2) syncope commonly induced by predisposing factors, such as rapid postural changes, prolonged upright positions and hot and stuffy environments; 3) a positive hemodynamic response in the HUTT; and 4) the exclusion of other causes of syncope-like events. Patients with a history of heart failure, hypertension or renal disease, and those without complete clinical information were excluded. Patients who refused to undergo ORS treatment were also excluded.

Protocol for the HUTT

The protocol for the HUTT and the positive response criteria were in accordance with those previously described. Three types of positive hemodynamic responses were identified according to the changes in heart rate and blood pressure: 1) a cardioinhibitory response, with an obvious reduction in heart rate and no marked decrease in blood pressure; 2) a vasoinhibitory response, with a marked decrease in blood pressure and no obvious reduction in heart rate; and 3) a mixed inhibitory response, with both an obvious blood pressure decrease and a significant heart rate reduction.

Measurement of BMI

BMI (kg/m²) was calculated as body weight (kg) divided by the square of height (m). For the measurement of body weight, subjects were required to wear only one layer of clothes and gently step onto a digital weighing scale. The reading was recorded when it became stable. To measure height with the use of a stadiometer, subjects were asked to take off their hats and shoes and remain in an upright position with their backs, buttocks and heels against a pole and their eyes looking forward. An operator adjusted the slide plate to drop down slowly and gently until there was contact between the cranial vertex and the bottom of the slide plate. All operators were trained in advance. BMI prior to treatment was regarded as the baseline BMI.

Treatment and follow-up

All included VVS patients received 5.125 g of ORS III (Anjian Pharma Company, Xi’an, China) daily. It contained 3.375 g of anhydrous glucose, 0.725 g of sodium citrate, 0.650 g of sodium chloride and 0.375 g of potassium chloride which were dissolved in 250 mL of water. ORS III has been produced since 2009 in China. Three months after starting therapy, the patients were followed up to assess their response to the intervention by telephone or during clinic visits. Questionnaires were used to evaluate therapeutic efficacy and adverse effects. Symptom scoring was used to reflect the severity of VVS, and the scores were calculated on the basis of the occurrence and frequency of syncopal and presyncopal events: 0, no syncope or presyncope; 1, once per month; 2, 2–4 events per month; 3, 2–7 events per week; 4, > once per day. The scoring system was used to assess each patient both before treatment and 3 months after follow-up. The therapeutic efficacy was determined to be effective when the symptom score decreased by at least 1 point, and correspondingly, these patients were considered “responders”; otherwise, they were considered “non-responders” [Figure 1]. All follow-up tasks were completed by the same professionally trained researcher.

Statistical analysis

SPSS 22.0 (IBM Corp, Armonk, NY, USA) was used for data analysis. Continuous variables were examined for normality using the Shapiro-Wilk test, and they are presented as the means and standard deviations or the medians (25th, 75th percentiles) as appropriate. Differences between two groups were analyzed using Student’s t test or the Mann-Whitney U test. Categorical variables are shown as frequencies and were compared with the chi-squared test. Predictors of response to ORS treatment were examined by forward stepwise logistic regression analysis. Correlations between nonnormally distributed parameters were evaluated with partial Spearman correlation coefficients to avoid potential confounders. A receiver operating characteristic (ROC) curve was drawn to evaluate the predictive ability of BMI for ORS treatment in children with VVS. The predictive value was represented by the area under the curve (AUC), with a low predictive value when the area was greater than 0.5 and less than or equal to 0.7, a moderate predictive value when the area was greater than 0.7 and less than or equal to 0.9 and a high predictive value when the area was >0.9. The maximum Youden index, which was calculated as sensitivity plus specificity minus 1, was used to determine the cut-off value. It was considered significant with a P value <0.05.

Results

Demographic, clinical and hemodynamic characteristics

Seventy-eight patients (41 females, aged 5–17 years; and 37 males, aged 6–16 years) with VVS receiving ORS treatment were included in the study, but four of them were subsequently lost to follow-up. Finally, 74 eligible patients (38 females, aged 6–17 years; and 36 males, aged
Sixty-eight VVS children treated with ORS were enrolled in the study. Of them, 48 (65%) patients had a vasoinhibitory response, 24 (32%) patients had a mixed inhibitory response and the remaining 2 (3%) patients had a cardioinhibitory response. No adverse effects were reported according to follow-up data. Based on the changes in symptom scores, 52 patients were defined as responders, and the other 22 were defined as non-responders. Between responders and non-responders, no difference was found in the symptom scores before treatment \((P = 0.886)\). However, the responders had much lower symptom scores at follow-up than the non-responders \((P < 0.001)\). Compared with the non-responders, the responders had short duration of symptoms before treatment \((P = 0.001)\) and low baseline BMI \((P < 0.001)\) [Table 1].

**Predictor of the therapeutic efficacy of ORS treatment**

Items with \(P\) values <0.1 in the univariate analysis (age at HUTT, duration of symptoms before treatment, baseline BMI and positive systolic blood pressure in HUTT), were included in the binary logistic regression analysis, and only the baseline BMI was determined to be an independent predictor of response to ORS treatment (odds ratio = 0.629, 95% Confidence interval [CI]: 0.500–0.792, \(P < 0.001)\).

**Correlation between baseline BMI and response time in HUTT**

To further explore whether the baseline BMI was associated with the severity of VVS, we performed a partial Spearman correlation test after adjusting for sex and found that the baseline BMI was positively correlated with response time in HUTT \((r = 0.256, 95\%\) CI: 0.067–0.439, \(P = 0.029)\) [Figure 2].

**Capability of baseline BMI to predict the response to ORS treatment in children with VVS**

To explore whether baseline BMI could predict the therapeutic efficacy of ORS, we applied ROC curve analysis. The area under the curve was 0.818 with a 95% CI of 0.704 to 0.932 \((P < 0.001)\) [Figure 3]. A baseline BMI of 18.9 kg/m² was determined to be the cut-off value for the maximum Youden index, with a sensitivity of 83% and a specificity of 73%.

**Discussion**

In this study, we observed that the baseline BMI of responders was much lower than that of non-responders. The baseline BMI showed a positive correlation with the response time in the HUTT. More importantly, a baseline BMI cut-off value of 18.9 kg/m² produced a relatively high value in predicting the response of children with VVS to ORS treatment.

Although the administration of ORS is relatively safe, we do not advise pediatricians to prescribe it nonselectively. Inappropriate ORS treatment would greatly limit its therapeutic efficacy, prolong the duration of symptoms and increase the economic burden of the families. Therefore, it has been important to determine a useful measure for predicting the therapeutic efficacy of supplementation with fluid and salt in pediatric VVS and to identify a more individualized treatment.

ORS is effective for VVS patients likely through the restoration of hypovolemia. After standing, an instantaneous shift of blood from the thorax to the lower extremities and splanchnic organs occurs. Decreased venous return to the heart is overt once the total blood volume is low, which leads to the decompensation reaction. Obviously, supplementing with fluid and salt can reverse the situation in patients whose predominant mechanism is hypovolemia. Disappointingly, heterogeneous and overlapping multifactorial mechanisms greatly reduce the value of this treatment. Blood volume can be...
calculated using isotopic or dye dilution techniques. However, the procedures for these techniques are complex and invasive. Two decades ago, Younoszai et al. investigated the value of an intravenous injection of 1 L of isotonic fluid during tilting to predict the efficacy of oral fluid therapy. A negative response to the tilt table test after intravenous injection predicted good efficacy of oral fluid therapy, with a sensitivity of 85% and a specificity of 20%. However, this method is invasive, time-consuming, and has the risk of inducing heart failure. Twenty-four-hour urinary sodium was reported to be correlated with blood volume and the severity of VVS. Recently, Zhang et al. observed that 109.5 mmol of 24-hour urinary sodium excretion had a sensitivity of 100% to predict the therapeutic efficacy of ORS, but its specificity was low (30.8%). Further study is required to determine its predictive value.

Previous studies have shown that BMI is positively related to blood volume and can predict the therapeutic efficacy of ORS in children diagnosed with postural orthostatic tachycardia syndrome, another common cause of pediatric syncope. Furthermore, people with lower BMI are more prone to experience syncope or respond positively to a HUTT than those with higher values. Therefore, we conducted the present study to evaluate whether baseline BMI had the capacity to predict the therapeutic efficacy of ORS treatment.

Table 1: Comparisons of characteristics of responders and non-responders in 74 patients with vasovagal syncope.

| Characteristics                        | All patients (n = 74) | Responders (n = 52) | Non-responders (n = 22) | Statistics | P values * |
|----------------------------------------|----------------------|---------------------|-------------------------|------------|-----------|
| Sex (female/male, n)                   | 38/36                | 26/26               | 12/10                   | 0.128      | 0.721     |
| Age at the first syncope event (years) | 8.7 ± 2.8            | 8.7 ± 2.8           | 8.7 ± 2.5               | -0.019     | 0.985     |
| Age at HUTT (years)                    | 10.0 (8.0, 13.0)     | 10.0 (8.0, 13.0)    | 11.5 ± 3.0              | -1.776     | 0.076     |
| Duration of symptoms before treatment (months) | 12.0 (3.8, 36.0) | 9.5 (2.0, 24.0)     | 34.3 ± 23.6             | -3.283     | 0.001     |
| Duration of treatment (months)         | 3.0 (2.0, 3.0)       | 2.5 (2.0, 3.0)      | 3.0 (2.0, 3.0)          | -0.043     | 0.966     |
| Body mass index (kg/m²) at baseline    | 17.1 (15.9, 19.4)    | 16.4 (15.5, 17.8)   | 20.7 ± 3.6              | -4.305     | < 0.001   |
| Symptom scores before treatment (points)| 1 (1, 1)            | 1 (1, 1)            | 1 (1, 1)                | -0.143     | 0.886     |
| Symptom scores at follow-up (points)   | 0 (0, 1)             | 0 (0, 0)            | 1 (1, 1)                | -7.777     | < 0.001   |
| Supine heart rate in HUTT (bpm)        | 75 (68, 80)          | 75 (70, 82)         | 71 ± 11                 | -1.640     | 0.101     |
| Supine systolic BP in HUTT (mmHg)      | 104 ± 9              | 104 ± 9             | 104 ± 8                 | -0.069     | 0.945     |
| Supine diastolic BP in HUTT (mmHg)     | 60 ± 8               | 61 ± 8              | 58 ± 8                  | -1.310     | 0.195     |
| Positive heart rate in HUTT (bpm)      | 75 (64, 114)         | 77 (63, 115)        | 73 (63, 114)            | -0.325     | 0.745     |
| Positive systolic BP in HUTT (mmHg)    | 75 (66, 83)          | 74 (65, 82)         | 80 ± 14                 | -1.698     | 0.089     |
| Positive diastolic BP in HUTT (mmHg)   | 42 ± 9               | 42 ± 9              | 44 ± 11                 | 1.116      | 0.268     |
| Response time in HUTT (minutes)        | 14 (10, 26)          | 14 (9, 26)          | 14 (10, 28)             | -0.563     | 0.574     |
| Hemodynamic type ratio of VVS (VI/[MI+CI], n) | 48/26               | 31/21               | 17/5                    | 2.115      | 0.146     |

Normally distributed data are presented as the mean ± standard deviation, otherwise as the median (25th, 75th percentiles). Categorical data are expressed as frequencies. *Comparisons between responders and non-responders. †x² value. ‡t value. *Z value. HUTT: Head-up tilt test; BP: Blood pressure; VVS: Vasovagal syncope; VI: Vasoinhibitory response; MI: Mixed inhibitory response; CI: Cardioinhibitory response.
In the present study, we found that the baseline BMI of the responders was much lower than that of the non-responders. Furthermore, we used response time in HUTT as a reasonable indicator of the severity of VVS, and it showed a positive correlation with baseline BMI, which suggested that baseline BMI was reasonably capable of reflecting the severity of this disease. With the help of ROC curve analysis, we found out for the first time, that baseline BMI was a promising predictor prior to treatment.

However, body blood volume is influenced by many cofactors aside from weight and height (which were used in calculating BMI), such as age, physical activity, climatic environment, hematocrit and autonomic nervous activity. All these cofactors codetermine the actual state of blood volume. Therefore, the value of application of BMI in predicting the efficacy of supplementation with fluid and salt could be lowered by such cofactors.

Some limitations should not be neglected in this study. The small sample size could have led to bias in the study conclusions. Additionally, the retrospective case-control study design could have resulted in an inevitable recall bias. In the future, prospective and larger sample multicenter studies seeking better indicators are needed for the implementation of individualized therapy in VVS patients.

Conclusions
Baseline BMI is a promising and practical way to predict the therapeutic response of children with VVS to ORS treatment, not only for its predictive capacity but also for its case of measurement and inexpensiveness. Our findings could help pediatricians implement individualized therapy efficiently and conveniently.

Acknowledgements
The authors thank the staff members of the Syncope Unit of Pediatrics at Peking University First Hospital for their assistance with diagnosing VVS patients, and also thank the patients and their guardians for their participation.

Funding
This work was supported by grants from the Peking University Medicine Fund of Fostering Young Scholars’ Scientific & Technological Innovation, Peking University Clinical Medicine Plus X - Young Scholars Project (PKU2019LCXQ011), the Peking University Clinical Scientist Program (No. BMU2019LCXJ001) and the Fundamental Research Funds for the Central Universities.

Conflicts of interest
None.

References
1. Chen L, Wang C, Wang H, Tian H, Tang C, Jin H, et al. Underlying diseases in syncope of children in China. Med Sci Monit 2011;17: H49-H53. doi: 10.12659/msm.881795.

2. Liao Y, Xu W, Li H, Tang C, Jin H, Du J. Plasma neuropeptide Y levels in vasovagal syncope in children. Chin Med J 2017;130:2778–2784. doi: 10.4103/0366-6999.219157.

3. Bai W, Chen S, Tang C, Qi J, Cui Q, Xu M, et al. Gut microbiota analysis and its significance in vasovagal syncope in children. Chin Med J 2019;132:411–419. doi: 10.1097/CM9.0000000000000886.

4. Vargas E, Worrum F, Szabó Z, Varga M, Lorincz I. Motor vehicle accident with complete loss of consciousness due to vasovagal syncope. Forensic Sci Int 2002;130:156–159. doi: 10.1016/S0379-0738(02)00377-8.

5. Lerma A, Lerma C, Márquez MF, Cardenas M, Hermosillo AG. Correlation of syncopal burden with anxiety symptoms score in recurrent vasovagal syncope. Int J Cardiol 2013;166:266–267. doi: 10.1016/j.jcard.2012.09.105.

6. Chen W, Wang C, Wu L, Lin P, Li F, Zou R. Oral rehydration salts: an effective choice for the treatment of children with vasovagal syncope. Pediatr Cardiol 2015;36:867–872. doi: 10.1007/s00246-015-1097-5.

7. Song J, Li H, Wang Y, Liu P, Li X, Tang C, et al. Changes of electrolytes in serum and urine in children with neurally mediated syncope cured by oral rehydration salts. Int J Cardiol 2017;233:125–129. doi: 10.1016/j.jcin.2016.12.138.

8. Mosquera-Garcia P, Furlan K, Fernandez-Violante R. The elusive pathophysiology of neurally mediated syncope. Circulation 2000;102:2898–2906. doi: 10.1161/01.CIR.102.23.2898.

9. Kenny RA, McNicholas T. The management of vasovagal syncope. QJM 2016;109:767–773. doi: 10.1093/qjmed/hcw089.

10. Wang C, Li YQ, Liao Y, Tian H, Huang M, Dong XY, et al. 2018 Chinese Pediatric Cardiology Society (CPCS) guideline for diagnosis and treatment of syncope in children and adolescents. Sci Bull 2018;63:1558–1564. doi: 10.1016/j.scib.2018.09.019.

11. Stewart JM, Taneja I, Medow MS. Reduced body mass index is associated with increased angiotensin II in young women with postural tachycardia syndrome. Clin Sci (Lond) 2007;113:449–457. doi: 10.1042/CS20070104.

12. Jain RB, Bernert JT. Effect of body mass index and total blood volume on serum cotinine levels among cigarette smokers: NHANES 1999–2008. Clin Chim Acta 2010;411:1063–1068. doi: 10.1016/j.chima.2010.03.040.

13. Cepeda-Lopez AC, Zimmermann MB, Wussler S, Melse-Boonstra A, Nael N, Mueller SM, et al. Greater blood volume and Hb mass in obese women quantified by the carbon monoxide-rebreathing method affects interpretation of iron biomarkers and iron requirements. Int J Obes (Lond) 2019;43:999–1008. doi: 10.1038/s41366-018-0127-9.

14. Ghristou GA, Kiortsis DN. The effects of body weight status on orthostatic intolerance and predisposition to noncardiac syncope. Obes Rev 2017;18:370–379. doi: 10.1111/obr.12501.

15. Luz Luiz Leiria T, Barcellos SR, Moraes MA, De Lima GG, Kus T, Barbisan JN. Low body mass index is associated with a positive response during a head-up tilt test. Pacing Clin Electrophysiol 2013;36:37–41. doi: 10.1111/pacj.12006.

16. Yamada T, Yanagimoto S. Dose-response relationship between the risk of vasovagal syncope and body mass index or systolic blood pressure in young adults undergoing blood tests. Neuropepiidemiology 2017;49:31–33. doi: 10.1159/000479696.

17. Chinese Pediatric Cardiology Society, Editorial Board of Chinese Journal of Pediatrics. Guideline for diagnosis of syncope in children. Chin J Pediatr 2009;47:99–101. doi: 10.3760/cma.j.issn.0578-1310.2009.02.006.

18. Chinese Pediatric Cardiology Society, Editorial Board of Chinese Journal of Pediatrics. Subspecialty Group of Cardiology of the Society of Pediatrics of Beijing Medical Association, Professional Board of Syncope in Children of Pediatrician Society of Chinese Medical Doctor Association. Guideline for diagnosis of syncope in children (updated in 2016). Chin J Pediatr 2016;54:246–250. doi: 10.37760/cma.jscc.0578-1310.2016.04.003.

19. Tao C, Li X, Tang C, Jin H, Du J. Acceleration index predicts efficacy of orthostatic training on vasovagal syncope in children. J Pediatr 2019;207:54–58. doi: 10.1016/j.jpeds.2018.10.063.

20. Tao C, Li X, Tang C, Jin H, Du J. Baroreflex sensitivity predicts response to metoprolol in children with vasovagal syncope: a pilot study. Front Neurosci 2019;13:1329. doi: 10.3389/fnins.2019.01329.

21. Song J, Li H, Wang Y, Liu P, Li X, Tang C, et al. Left ventricular ejection fraction and fractional shortening are useful for the
prediction of the therapeutic response to metoprolol in children with vasovagal syncope. Pediatr Cardiol 2018;39:1366–1372. doi: 10.1007/s00246-018-1904-x.
22. Germans MR, de Witt Hamer PC, van Boven LJ, Zwinderman KA, Bouma GJ. Blood volume measurement with indocyanine green pulse spectrophotometry: dose and site of dye administration. Acta Beurochir (Wien) 2010;152:251–255. doi: 10.1007/s00701-009-0501-4.
23. Younoszai AK, Franklin WH, Chan DP, Cassidy SC, Allen HD. Oral fluid therapy. A promising treatment for vasodepressor syncope. Arch Pediatr Adolesc Med 1998;152:165–168. doi: 10.1016/S0929-693X(97)86844-3.
24. El-Sayed H, Hainsworth R. Salt supplement increases plasma volume and orthostatic tolerance in patients with unexplained syncope. Heart 1996;75:134–140. doi: 10.1136/hrt.75.2.134.
25. Hampton JL, Parry SW, Kenny RA, Newton JL. Lower 24 hour urinary sodium concentrations are associated with more severe symptoms in subjects with vasovagal syncope. Heart 2004;90:687–688. doi: 10.1136/hrt.2003.020115.
26. Li H, Wang Y, Liu P, Chen Y, Feng X, Tang C, et al. Body mass index (BMI) is associated with the therapeutic response to oral rehydration solution in children with postural tachycardia syndrome. Pediatr Cardiol 2016;37:1313–1318. doi: 10.1007/s00246-016-1436-1.
27. Gielerak G, Makowski K, Cholewa M. Prognostic value of head-up tilt test with intravenous beta-blocker administration in assessing the efficacy of therapy in patients with vasovagal syncope. Ann Noninvasive Electrocardiol 2005;10:63–72. doi: 10.1111/j.1542-474X.2005.00603.x.
28. Jang WJ, Youm HR, Lee SH, Park SJ, Kim JS, Oh YK. Prognosis after tilt training in patients with recurrent vasovagal syncope. Int J Cardiol 2013;168:4264–4265. doi: 10.1016/j.ijcard.2013.04.123.
29. Koons NJ, Suresh MR, Schlotman TE, Convertino VA. Interrelationship between sex, age, blood volume, and Vo2max. Aerosp Med Ham Perform 2019;90:362–368. doi: 10.3357/AMHP.5235.2019.
30. Convertino VA. Blood volume response to physical activity and inactivity. Am J Med Sci 2007;334:72–79. doi: 10.1097/MAJ.0b013e318063c6e4.
31. Wadsworth GR. Blood-volume: a commentary. Singapore Med J 2002;43:426–431.
32. Dunn A, Lo V, Donnelly S. The role of the kidney in blood volume regulation: the kidney as a regulator of the hematocrit. Am J Med Sci 2007;334:65–71. doi: 10.1097/MAJ.0b013e318095a4ae.
33. Biaggioni I. The sympathetic nervous system and blood volume regulation: lessons from autonomic failure patients. Am J Med Sci 2007;334:61–64. doi: 10.1097/MAJ.0b013e318056c03b.